Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite, which was extended on this side of the pond due to a holiday, was somehow relaxing and refreshing. Well, regardless, the usual routine of Zoom meetings, Skype calls and deadlines has predictably returned. What can you do? The world keeps spinning, no matter what. So hold on tight, grab a cup of stimulation, and feel free to peruse the tidbits we have assembled for you. Hope your day goes well, and do keep in touch. One more thing, stay safe and wear a mask. …

Researchers have designed a staggering 1,200 clinical trials aimed at testing treatment and prevention strategies against Covid-19 since the start of January, but a new STAT analysis shows the effort has been marked by disorder and disorganization, with huge financial resources wasted. For instance, one in every six trials was designed to study the decades-old malaria drugs hydroxychloroquine or chloroquine, which have been shown to have no benefit in hospitalized patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.